CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease

European Journal of Neurology

Volumn 15, Issue 11, 2008, Pages 1155-1162

  Haense, C ^a   Buerger, K ^b   Kalbe, E ^c   Drzezga, A ^d   Teipel, S J ^b,e   Markiewicz, P ^f   Herholz, K ^c,f   Heiss, W D ^a   Hampel, H ^b,g  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF ROSTOCK   (Germany)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

18F FDG PET; CSF phosphorylated tau; CSF total tau; Dementia severity; Glucose metabolism

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; P TAU THREONINE 181 PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; CEREBROSPINAL FLUID; CINGULATE GYRUS; CLINICAL ARTICLE; CORRELATION ANALYSIS; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; LEFT HEMISPHERE; MALE; METABOLIC DISORDER; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; BRAIN MAPPING; DISABILITY EVALUATION; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 53549134259     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02274.x     Document Type: Article

References (53)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, 4th edn. Washington, D.C. : American Psychiatric Association, 1994.
2. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica 1991 82 : 239 259.
3. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. Tau is essential to beta -amyloid-induced neurotoxicity. Proceedings of the National Academy of Sciences USA 2002 99 : 6364 6369.
4. Blennow K, Vanmechelen E, Hampel H. CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease. Molecular Neurobiology 2001 24 : 87 97.
5. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurology 2003 2 : 605 613.
6. Hampel H, Buerger K, Zinkowski R, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Archives of General Psychiatry 2004 61 : 95 102.
7. Frank RA, Galasko D, Hampel H, et al. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiology of Aging 2003 24 : 521 536.
8. Andreasen N, Vanmechelen E, Van de Voorde A, et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. Journal of Neurology, Neurosurgery and Psychiatry 1998 64 : 298 305.
9. Hock C, Golombowski S, Naser W, Muller-Spahn F. Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease - correlation with degree of cognitive impairment. Annals of Neurology 1995 37 : 414 415.
10. Skoog I, Vanmechelen E, Andreasson LA, et al. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 1995 4 : 433 442.
11. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 2002 17 : 302 316.
12. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA 2001 286 : 2120 2127.
13. Choo IH, Lee DY, Youn JC, et al. Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study. Alzheimer Disease and Associated Disorders 2007 21 : 77 84.
14. Salmon E, Collette F, Degueldre C, Lemaire C, Franck G. Voxel-based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's disease. Human Brain Mapping 2000 10 : 39 48.
15. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003 60 : 1374 1377.
16. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry 2004 9 : 705 710.
17. Fellgiebel A, Siessmeier T, Scheurich A, et al. Association of elevated phospho-tau levels with Alzheimer-typical 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biological Psychiatry 2004 56 : 279 283.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34 : 939 944.
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975 12 : 189 198.
20. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test: Adult Version Manual. San Antonio, TX : The Psychological Corporation, 1987.
21. Rey A. L'examen psychologique dans les cas d'encephalopathie traumatique. Archives de Psychologie 1941 28 : 286 340.
22. Härting C, Markowitsch HJ, Neufeld H, Calabrese P, Deisinger K, Kessler J. Wechsler Gedächtnistest - Revidierte Fassung (WMS-R), Testmanual, deutsche Adaptation der revidierten Fassung der Wechsler memory Scale von David Wechsler. Bern : Hans Huber, 2000.
23. Reitan RM. Trail Making Test: Manual for Administration and Scoring. Tucson, AZ : Reitan Neuropsychology Laboratory, 1986.
24. Stroop JR. Studies of interference in serial verbal reaction. Journal of Experimental Psychology 1935 18 : 643 662.
25. Spreen O, Strauss E. A Compendium of Neuropsychological Tests - Administration, Norms and Commentary. New York : Oxford University Press, 1998.
26. Huber W, Poeck K, Weniger D, Willmes K. Aachener Aphasie Test (AAT) - Handanweisung. Göttingen : Hogrefe, 1983.
27. Kaplan E, Goodglass H, Weintraub S, Segal O. Boston Naming Test. Philadelphia, PA : Lea & Febiger, 1978.
28. Atkinson RC, Shiffrin RM. The control of short-term memory. Scientific American 1971 225 : 82 90.
29. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984 141 : 1356 1364.
30. Schmidt KH, Metzler P. Wortschatztest (WST). Weinheim : Beltz, 1992.
31. Oswald WD, Fleischmann UM. Das Nürnberger-Alters-Inventar (NAI). Göttingen : Hogrefe, 1995.
32. Holmes CJ, Hoge R, Collins L, Woods R, Toga AW, Evans AC. Enhancement of MR images using registration for signal averaging. Journal of Computer Assisted Tomography 1998 22 : 324 333.
33. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. Journal of Computer Assisted Tomography 1995 19 : 541 547.
34. Zuendorf G, Kerrouche N, Herholz K, Baron JC. An efficient principal component analysis for multivariate 3D voxel-based mapping of brain functional imaging data sets as applied to FDG-PET and normal aging. Human Brain Mapping 2003 18 : 13 21.
35. Herholz K. PET studies in dementia. Annals of Nuclear Medicine 2003 17 : 79 89.
36. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Annals of Neurology 1991 30 : 572 580.
37. Desgranges B, Baron JC, de la Sayette V, et al. The neural substrates of memory systems impairment in Alzheimer's disease A PET study of resting brain glucose utilization. Brain 1998 121 (Pt 4 611 631.
38. Slansky I, Herholz K, Pietrzyk U, et al. Cognitive impairment in Alzheimer's disease correlates with ventricular width and atrophy-corrected cortical glucose metabolism. Neuroradiology 1995 37 : 270 277.
39. Haxby JV, Grady CL, Koss E, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Archives of Neurology 1990 47 : 753 760.
40. Desgranges B, Baron JC, Lalevee C, et al. The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. Brain 2002 125 : 1116 1124.
41. Ivanoiu A, Sindic CJ. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase 2005 11 : 32 39.
42. Desgranges B, Baron JC, Lalevee C, et al. The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. Brain 2002 125 : 1116 1124.
43. Vigo-Pelfrey C, Seubert P, Barbour R, et al. Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer's disease. Neurology 1995 45 : 788 793.
44. Sunderland T, Wolozin B, Galasko D, et al. Longitudinal stability of CSF tau levels in Alzheimer patients. Biological Psychiatry 1999 46 : 750 755.
45. Mollenhauer B, Bibl M, Trenkwalder C, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. Journal of Neural Transmission 2005 112 : 933 948.
46. Tapiola T, Pirttila T, Mikkonen M, et al. Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. Neuroscience Letters 2000 280 : 119 122.
47. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 2006 5 : 228 234.
48. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005 64 : 1294 1297.
49. Wallin AK, Blennow K, Andreasen N, Minthon L. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dementia and Geriatric Cognitive Disorders 2006 21 : 131 138.
50. Geldmacher DS, Frolich L, Doody RS, et al. Realistic expectations for treatment success in Alzheimer's disease. Journal of Nutrition, Health & Aging 2006 10 : 417 429.
51. Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2003 2 : 506 511.
52. Buerger K, Alafuzoff I, Ewers M, Pirttila T, Zinkowski R, Hampel H. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2007 130 : e82.
53. Buerger K, Ewers M, Pirttila T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006 129 : 3035 3041.